Author

John E. Schmeling

Observed names: J. Schmeling, John Schmeling

Institutions: Mayo Clinic, Centre Hospitalier Universitaire de Martinique

Observed institutions: Mayo Clinic, Centre Hospitalier Universitaire de Martinique

OpenAlex ID: A5028997455

Expanded phenotypes and outcomes among 256 LGI 1/ CASPR 2‐ I g G –positive patients

2017 · Avi Gadoth, Sean J. Pittock, et al. · Annals of Neurology · 362

Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases

2017 · Divyanshu Dubey, Vanda A. Lennon, et al. · Neurology · 131

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD

2020 · Jiraporn Jitprapaikulsan, James P. Fryer, et al. · Neurology Neuroimmunology & Neuroinflammation · 66

Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka

2019 · Bimsara Senanayake, Jiraporn Jitprapaikulsan, et al. · Journal of Neurology Neurosurgery & Psychiatry · 40

Clinical utility of testing cerebrospinal fluid (CSF) for AQP4-IgG: A guideline to improve physician ordering of AQP4-IgG diagnostic test. (S12.003)

2016 · Masoud Majed, James Fryer, et al. · Neurology · 1

Diagnostic utility and seroprevalence of AQP4/MOG-IgG in a consecutive cohort of patients undergoing evaluation for suspected CNS inflammatory demyelinating disorders: Mayo clinic/Sri Lankan collaborative study

2017 · B. Senanayake, J. Wijesekera, et al. · Journal of the Neurological Sciences

Epidemiology of Aquaporin-4 Autoimmunity and Neuromyelitis Optica Spectrum: A Comparison of Two Ethnically Divergent Populations (P3.003)

2016 · Eoin Flanagan, Philippe Cabre, et al. · Neurology

Works count: 7

Citation count: 600

H-index: 4

I10-index: 4